DSIP 10mg Peptide: Research Guide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu)
By UK Peptide Lab Research Team•19 September 2026•6 min read
Key Takeaways
- DSIP 10mg is the higher-mass research format of the delta sleep-inducing peptide: nonapeptide Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, MW 848.8 g/mol, CAS 62568-57-4, first isolated from rabbit cerebral venous blood (Schoenenberger and Monnier, PNAS, 1977).
- No DSIP receptor or encoding gene has ever been identified, and the original sleep findings have resisted consistent replication; the field's reviewers describe it as a 'still unresolved riddle' (Kovalzon and Strekalova, J Neurochem, 2006).
- Human evidence is thin and mixed: early trials reported some sleep effects, but a double-blind study in chronic insomniacs found them too weak for therapeutic use (Bes et al., Neuropsychobiology, 1992).
- Supplied for in-vitro laboratory research only: no dosing information, no human-use claims, no therapeutic promises.
What is DSIP 10mg?
DSIP (delta sleep-inducing peptide) is a nine-residue neuropeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, molecular weight 848.8 g/mol and CAS number 62568-57-4. The name describes the observation behind its discovery rather than any known mechanism: the peptide was named for the delta-wave electroencephalogram activity it appeared to promote. UK Peptide Lab supplies DSIP 10mg as the higher-mass research format of our 5mg vial, presenting twice the peptide mass per vial. Supplied as lyophilised powder for in-vitro laboratory research use only.
Origin: A Peptide Named for an EEG Pattern
DSIP was isolated by the Schoenenberger and Monnier group at Basel and reported in the Proceedings of the National Academy of Sciences in 1977. The source material was cerebral venous blood from rabbits in which slow-wave sleep had been induced by electrical stimulation of the intralaminar thalamus; intraventricular infusion of the isolated material enhanced delta and spindle EEG activity in recipient animals. The synthetic nonapeptide reproduced the effect, and the name stuck.
Sleep Architecture Research
The sleep literature that followed is best described as mixed. Graf and Kastin's review (Neurosci Biobehav Rev, 1984) summarised reports of delta-sleep enhancement in rabbits, rats, mice and humans alongside a much wider list of claimed activities. Early human work described effects on disturbed sleep (Schneider-Helmert and Schoenenberger, Neuropsychobiology, 1983), but a double-blind matched-pairs study in 16 chronic insomniac patients found weak, partly confounded effects and concluded that short-term treatment 'is not likely to be of major therapeutic benefit' (Bes et al., Neuropsychobiology, 1992). The field never converged on a robust sleep effect.
Stress Hormone Regulation and Circadian Rhythms
A second strand sits some distance from sleep. In-vitro work reported that DSIP inhibited corticotropin-releasing factor-induced ACTH secretion from rat anterior pituitary tissue (Okajima and Hertting, Horm Metab Res, 1986), and Graf and Kastin's review catalogued reported effects on circadian and locomotor patterns. Stress hormone regulation and circadian rhythms remain the active lines of enquiry in a field that has largely outgrown the peptide's name.
An Honest Caveat: the Unresolved Riddle
No DSIP receptor has ever been identified, no gene encoding the peptide has been found in any sequenced genome, and whether it exists endogenously at all remains open nearly fifty years after its description. Kovalzon and Strekalova (J Neurochem, 2006) summarised the field under the title 'a still unresolved riddle', noting that the sleep-factor hypothesis is 'extremely poorly documented'. Human evidence remains limited, no marketing authorisation exists anywhere, and this guide therefore carries no dosing information and no human-use claims.
Laboratory Handling
Store the lyophilised vial at -20°C, protected from light and moisture. Reconstitute with bacteriostatic water injected slowly down the inner glass wall, then swirl gently until clear and colourless; never shake or vortex. The N-terminal tryptophan is the oxidation- and light-sensitive residue, so keep solutions cold, protect them from light, and prepare single-use aliquots. See the peptide storage guide.
Sourcing in the UK
UK Peptide Lab supplies research-grade DSIP 10mg at £27.99 as lyophilised powder, supplier-tested, batch UKPL-9513 at 98.80% purity by HPLC, with the certificate published on the product page. Independent third-party verification is pending. Same-day UK dispatch on orders before 2pm GMT, free Royal Mail Tracked shipping over £45. For in-vitro laboratory research use only, not for human consumption.
Related Products
Disclaimer: This article is for research and educational purposes only. All information provided is not intended as medical advice. UK Peptide Lab products are not for human consumption and are sold strictly for laboratory research use only.
Frequently Asked Questions
What is DSIP 10mg?
DSIP 10mg is the higher-mass research format of UK Peptide Lab's DSIP vial. The compound is the delta sleep-inducing peptide, a nine-residue neuropeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, molecular weight 848.8 g/mol and CAS 62568-57-4, first isolated from rabbit cerebral venous blood (Schoenenberger and Monnier, PNAS, 1977). Supplied as lyophilised powder for in-vitro laboratory research only.
Does DSIP work as a sleep aid?
No such claim can be made. The original sleep findings have resisted consistent replication, and the controlled human study concluded that short-term treatment was unlikely to offer major therapeutic benefit (Bes et al., Neuropsychobiology, 1992). DSIP holds no marketing authorisation, and this guide carries no dosing information and no human-use claims. Research use only.
How should DSIP 10mg be reconstituted?
Inject bacteriostatic water slowly down the inner wall of the vial and swirl gently until the solution is clear and colourless; never shake or vortex. Store lyophilised vials at -20°C and the reconstituted solution at 2-8°C, protected from light, using within approximately 4 weeks. Research use only.
References
- [1] Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proc Natl Acad Sci U S A (1977). View →
- [2] Delta-sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev (1984). View →
- [3] Effects of DSIP in man: multifunctional psychophysiological properties besides induction of natural sleep. Neuropsychobiology (1983). View →
- [4] Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients: a double-blind study. Neuropsychobiology (1992). View →
- [5] Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem (2006). View →